Replies to post #103337 on Biotech Values

[DewDiligence]

SNY is flat today, but they've already guided for poor Lovenox sales.

SNY’s revised EPS guidance for 2010 does not allow for a third Lovenox entrant (or an AG launch) in the US market unless one makes assumptions that are significantly different from mine—please see #msg-53835981.